CardioFocus HeartLight® Demonstrates High-Dose Visually Guided Laser Ablation Superior to Low-Dose Ablation in New Study

CardioFocus HeartLight® Demonstrates High-Dose Visually Guided Laser Ablation Superior to Low-Dose Ablation in New Study PR Newswire MARLBOROUGH, Massachusetts, Nov. 19, 2012 - Data Published in EP-Europace shows high-dose ablation results in acute PVI rate of 89% and long-term success rate of 83% off antiarrhythmic drugs after a single procedure MARLBOROUGH, Massachusetts, Nov. 19, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announces new data demonstrating the superior benefits of high-dose laser ablation compared to low-dose treatment. Using the HeartLight System, investigators in Frankfurt, Germany were able to achieve an acute PVI rate of 89% after an initial visually guided ablation circle and reported a long-term clinical success rate of 83% off antiarrhythmic drugs after a single procedure. The data, representing the first examination of varying laser ablation energy on both the acute and long-term outcomes in patients with drug refractory AF, is published in the November 2012 online issue of EP-Europace — The European Journal of Pacing, Arrhythmias and Cardiac Electrophysiology of the European Heart Rhythm Association of the European Society of Cardiology.